Announcements Trials
Browse Landscape

Phase

Phase 2 31Phase 4 7Phase 3 6Phase 1 3Phase NA 2

Status

Unknown 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1

Conditions

Pancreatic Neoplasms 2Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 49fludarabine 37Injections 32Gemcitabine 24Paclitaxel 23Cisplatin 21pembrolizumab 19Radiotherapy 19toripalimab 18Carboplatin 17Capecitabine 17Fluorouracil 15Oxaliplatin 13Nivolumab 12Docetaxel 12camrelizumab 11apatinib 11Temozolomide 11Cetuximab 11Bevacizumab 10Irinotecan 9Immunotherapy, Adoptive 9Drug Therapy 9Etoposide 8sintilimab 7Radiosurgery 7Peripheral Blood Stem Cell Transplantation 7Leucovorin 7Ipilimumab 7Indium 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Unknown × icotinib × Clear all
NCT02024633 2015-07-15

Combination of Icotinib and Gemcitabine as First-line Treatment in Pancreatic Cancer

Betta Pharmaceuticals Co., Ltd.

Phase 1 Unknown
24 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT02278458 2015-05-22

Combination of Icotinib and Gemcitabine as First-line Treatment in Pancreatic Cancer

Betta Pharmaceuticals Co., Ltd.

Phase 1 Unknown
24 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT02066870 2015-03-13

Icotinib and Arsenic Trioxide in Treating Non-small-cell Lung Cancer Patients With Resistance to EGFR-TKI

Betta Pharmaceuticals Co., Ltd.

Phase 1 Unknown
9 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡